US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
US6583168B1
(en)
|
1997-11-25 |
2003-06-24 |
Applera Corporation |
Sulfonated diarylrhodamine dyes
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
WO1999060855A1
(en)
|
1998-05-26 |
1999-12-02 |
Icn Pharmaceuticals, Inc. |
Novel nucleosides having bicyclic sugar moiety
|
US6548651B1
(en)
|
1998-11-11 |
2003-04-15 |
Pantheco A/S |
Modified peptide nucleic acid (PNA) molecules
|
CA2388991A1
(en)
*
|
1998-11-11 |
2001-04-19 |
Peter E. Nielsen |
Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
|
JP4148662B2
(ja)
*
|
2000-08-10 |
2008-09-10 |
第一三共株式会社 |
ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
|
ID30093A
(id)
|
1999-02-12 |
2001-11-01 |
Sankyo Co |
Analog-analog nukleosida dan oligonukleotida baru
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
EP1161439B1
(en)
*
|
1999-03-18 |
2010-04-21 |
Exiqon A/S |
Xylo-lna analogues
|
EP1161554B1
(en)
|
1999-03-18 |
2011-03-09 |
Exiqon A/S |
Detection of mutations in genes by specific lna primers
|
DE60025172T2
(de)
|
1999-03-18 |
2006-09-21 |
Exiqon A/S |
Einstufige probezubereitung und bestimmung von nukleinsäure in biologischen proben
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
AU3418800A
(en)
*
|
1999-03-24 |
2000-10-09 |
Exiqon A/S |
Improved synthesis of (2.2.1)bicyclo nucleosides
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
ES2283298T3
(es)
*
|
1999-05-04 |
2007-11-01 |
Santaris Pharma A/S |
Analogos de l-ribo-lna.
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
DE19926154A1
(de)
|
1999-06-09 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
|
US6593466B1
(en)
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
JP4151751B2
(ja)
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
WO2001025478A1
(en)
*
|
1999-10-04 |
2001-04-12 |
Exiqon A/S |
A method of increasing the specificity of oxy-lna oligonucleotides
|
JP2003511016A
(ja)
*
|
1999-10-04 |
2003-03-25 |
エクシコン エ/エス |
オリゴヌクレオチドを補充する高親和性rnアーゼhの設計
|
EP1240322A2
(en)
*
|
1999-12-23 |
2002-09-18 |
Exiqon A/S |
Therapeutic uses of lna-modified oligonucleotides
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US6936467B2
(en)
|
2000-03-27 |
2005-08-30 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
WO2001073002A2
(en)
*
|
2000-03-27 |
2001-10-04 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
AU2001249622B2
(en)
|
2000-03-30 |
2007-06-07 |
Massachusetts Institute Of Technology |
RNA sequence-specific mediators of RNA interference
|
US6887664B2
(en)
|
2000-06-06 |
2005-05-03 |
Applera Corporation |
Asynchronous primed PCR
|
JP2002322192A
(ja)
*
|
2000-08-10 |
2002-11-08 |
Sankyo Co Ltd |
2’−o,4’−c−架橋ヌクレオシドトリリン酸体
|
DK1334109T3
(da)
|
2000-10-04 |
2006-10-09 |
Santaris Pharma As |
Forbedret syntese af purin-blokerede nukleinsyre-analoger
|
DE60138714D1
(de)
|
2000-10-11 |
2009-06-25 |
Applera Corp |
Fluoreszierende nukleobasekonjugate mit anionische linker
|
WO2002044321A2
(en)
|
2000-12-01 |
2002-06-06 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference mediating small rna molecules
|
US6720148B1
(en)
|
2001-02-22 |
2004-04-13 |
Caliper Life Sciences, Inc. |
Methods and systems for identifying nucleotides by primer extension
|
EP1247815A3
(en)
*
|
2001-03-25 |
2003-01-29 |
Exiqon A/S |
Modified oligonucleotides and uses thereof
|
WO2002079495A2
(en)
|
2001-03-27 |
2002-10-10 |
University Of Delaware |
Genomics applications for modified oligonucleotides
|
WO2002079467A2
(en)
*
|
2001-03-29 |
2002-10-10 |
Københavns Universitet |
Antibiotic-free bacterial strain selection with antisense molecules
|
EP1251183A3
(en)
*
|
2001-04-18 |
2003-12-10 |
Exiqon A/S |
Improved helper probes for detection of a target sequence by a capture oligonucleotide
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
WO2002094250A2
(en)
*
|
2001-05-18 |
2002-11-28 |
Cureon A/S |
Therapeutic uses of lna-modified oligonucleotides in infectious diseases
|
US20030032028A1
(en)
*
|
2001-06-12 |
2003-02-13 |
Gayle Dace |
In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads
|
WO2002101041A1
(fr)
*
|
2001-06-12 |
2002-12-19 |
Takara Bio Inc. |
Procede d'amplification de l'acide nucleique et procede de detection du polymorphisme des nucleotides a l'aide d'un analogue de nucleotide
|
US7053195B1
(en)
|
2001-06-12 |
2006-05-30 |
Syngenta Participatious Ag |
Locked nucleic acid containing heteropolymers and related methods
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
CA2633413C
(en)
|
2001-06-20 |
2012-08-21 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7153954B2
(en)
|
2001-07-12 |
2006-12-26 |
Santaris Pharma A/S |
Method for preparation of LNA phosphoramidites
|
WO2003006477A1
(en)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
|
US6822088B2
(en)
|
2001-07-17 |
2004-11-23 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides on solid support
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US7060809B2
(en)
|
2001-09-04 |
2006-06-13 |
Exiqon A/S |
LNA compositions and uses thereof
|
ATE516042T1
(de)
|
2001-09-18 |
2011-07-15 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
|
US7414111B2
(en)
|
2001-09-19 |
2008-08-19 |
Alexion Pharmaceuticals, Inc. |
Engineered templates and their use in single primer amplification
|
AU2002341752B2
(en)
|
2001-09-19 |
2008-04-03 |
Alexion Pharmaceuticals, Inc. |
Engineered templates and their use in single primer amplification
|
WO2003027265A2
(en)
|
2001-09-27 |
2003-04-03 |
University Of Delaware |
Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
|
US7468244B2
(en)
|
2001-09-27 |
2008-12-23 |
University Of Delaware |
Polymorphism detection and separation
|
AU2002334895B2
(en)
|
2001-10-09 |
2006-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
WO2003033696A1
(fr)
*
|
2001-10-18 |
2003-04-24 |
Sankyo Company, Limited |
Compose antisens vegf
|
WO2003039523A2
(en)
*
|
2001-11-05 |
2003-05-15 |
Exiqon A/S |
OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
|
EP1442137A4
(en)
|
2001-11-07 |
2005-08-31 |
Applera Corp |
UNIVERSAL NUCLEOTIDES FOR NUCLEIC ACID ANALYSIS
|
EP2196544A1
(en)
|
2001-11-21 |
2010-06-16 |
Applied Biosystems, LLC |
Kit for ligation detection assays using codeable labels
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
WO2003052128A1
(en)
*
|
2001-12-19 |
2003-06-26 |
Quantibact A/S |
A method and a kit for determination of a microbial count
|
EP2067472A1
(en)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
DE60331297D1
(de)
|
2002-03-07 |
2010-04-01 |
Univ Delaware |
Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
|
HUE037352T2
(hu)
|
2002-04-05 |
2018-08-28 |
Roche Innovation Ct Copenhagen As |
A HIF-1alfa expresszálódását módosító oligomer vegyületek
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20040014957A1
(en)
*
|
2002-05-24 |
2004-01-22 |
Anne Eldrup |
Oligonucleotides having modified nucleoside units
|
US20040014108A1
(en)
*
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
AU2003248708A1
(en)
*
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
US7005265B1
(en)
|
2002-06-20 |
2006-02-28 |
Wenhong Fan |
Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
|
US20050053942A1
(en)
*
|
2002-06-24 |
2005-03-10 |
Sakari Kauppinen |
Methods and systems for detection and isolation of a nucleotide sequence
|
FI20021325A0
(fi)
|
2002-07-05 |
2002-07-05 |
Valtion Teknillinen |
Menetelmä ja reagenssipakkaus yksittäisten polynukleotidien määrän määrittämiseksi
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003267785C1
(en)
|
2002-09-13 |
2009-12-24 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
EP1549767A4
(en)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
MODULATION OF FORKHEAD BOX O1A GENE EXPRESSION
|
EP1556510A2
(en)
*
|
2002-10-21 |
2005-07-27 |
Exiqon A/S |
Oligonucleotide analogues for detecting and analyzing nucleic acids
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
AU2003287502B2
(en)
|
2002-11-05 |
2010-12-09 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003291753B2
(en)
*
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
EP2336319A1
(en)
|
2002-11-13 |
2011-06-22 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
DK2284269T3
(en)
|
2002-11-18 |
2017-10-23 |
Roche Innovation Ct Copenhagen As |
Antisense design
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
CA2942791C
(en)
|
2002-11-25 |
2019-08-20 |
Masafumi Matsuo |
Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
|
US20040115634A1
(en)
|
2002-12-11 |
2004-06-17 |
Isis Pharmaceuticals, Inc. |
Modulation of stat 6 expression
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
CA2515623A1
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of survivin expression
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
WO2004074503A2
(en)
*
|
2003-02-21 |
2004-09-02 |
Hoser Mark J |
Nucleic acid sequencing methods, kits and reagents
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
DE602004023279D1
(de)
|
2003-03-21 |
2009-11-05 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
CA2519241A1
(en)
|
2003-04-01 |
2004-11-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
US7799525B2
(en)
|
2003-06-17 |
2010-09-21 |
Human Genetic Signatures Pty Ltd. |
Methods for genome amplification
|
CN1833034B
(zh)
|
2003-06-20 |
2014-04-16 |
埃克斯魁恩公司 |
用于分析核酸混合物的探针、文库和试剂盒及其构建方法
|
US8969314B2
(en)
|
2003-07-31 |
2015-03-03 |
Regulus Therapeutics, Inc. |
Methods for use in modulating miR-122a
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
ATE555118T1
(de)
|
2003-08-28 |
2012-05-15 |
Takeshi Imanishi |
Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
|
DE602004018801D1
(de)
|
2003-09-04 |
2009-02-12 |
Human Genetic Signatures Pty |
Nukleinsäurenachweistest
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
EP2256200A3
(en)
|
2003-09-18 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E expression
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ATE404697T1
(de)
|
2003-11-07 |
2008-08-15 |
Daiichi Sankyo Co Ltd |
Verfahren zum nachweis von genetischem polymorphismus
|
US7439341B2
(en)
|
2003-11-14 |
2008-10-21 |
Integrated Dna Technologies, Inc. |
Fluorescence quenching azo dyes, their methods of preparation and use
|
CA2747871C
(en)
|
2003-11-17 |
2018-04-10 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US7504495B2
(en)
|
2003-11-20 |
2009-03-17 |
Exiqon A/S |
Quencher compositions comprising anthraquinone moieties
|
RU2377301C2
(ru)
|
2003-12-23 |
2009-12-27 |
Сантарис Фарма А/С |
ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
|
US20050164271A1
(en)
|
2004-01-20 |
2005-07-28 |
Sanjay Bhanot |
Modulation of glucocorticoid receptor expression
|
US7858769B2
(en)
|
2004-02-10 |
2010-12-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US8192937B2
(en)
|
2004-04-07 |
2012-06-05 |
Exiqon A/S |
Methods for quantification of microRNAs and small interfering RNAs
|
WO2005105157A2
(en)
|
2004-04-23 |
2005-11-10 |
The Trustees Of Columbia University In The City Ofnew York |
INHIBITION OF HAIRLESS PROTEIN mRNA
|
US8168777B2
(en)
|
2004-04-29 |
2012-05-01 |
Human Genetic Signatures Pty. Ltd. |
Bisulphite reagent treatment of nucleic acid
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
CN101056883B
(zh)
|
2004-09-10 |
2012-10-10 |
人类遗传标记控股有限公司 |
包括含有嵌入性假核苷酸(ipn)的嵌入性核酸(ina)的扩增阻断剂
|
CA2581174A1
(en)
|
2004-09-16 |
2006-03-30 |
Applera Corporation |
Fluorescent dye compounds, conjugates and uses thereof
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
EP1824975B9
(en)
|
2004-11-09 |
2011-04-20 |
Santaris Pharma A/S |
Lna oligonucleotides and the treatment of cancer
|
CA2587173C
(en)
|
2004-11-09 |
2016-09-06 |
Santaris Pharma A/S |
Potent lna oligonucleotides for the inhibition of hif-1a expression
|
NZ555620A
(en)
|
2004-12-03 |
2008-08-29 |
Human Genetic Signatures Pty |
Methods for simplifying microbial nucleic acids by chemical modification of cytosines
|
EP1838870A2
(en)
|
2004-12-29 |
2007-10-03 |
Exiqon A/S |
NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
|
AU2006204006A1
(en)
|
2005-01-06 |
2006-07-13 |
Applera Corporation |
Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
|
ZA200707490B
(en)
|
2005-03-10 |
2008-12-31 |
Genentech Inc |
Methods and compositions for modulatiing vascular integrity
|
US20090264635A1
(en)
|
2005-03-25 |
2009-10-22 |
Applera Corporation |
Methods and compositions for depleting abundant rna transcripts
|
AU2006230436B2
(en)
|
2005-03-31 |
2011-11-24 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
EP1902142B1
(en)
|
2005-04-14 |
2010-01-06 |
Applied Biosystems, LLC |
3'modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes
|
US7838502B2
(en)
|
2005-05-06 |
2010-11-23 |
University Of Massachusetts Medical School |
Compositions and methods to modulate H. influenzae pathogenesis
|
EP1893043A4
(en)
|
2005-05-11 |
2013-07-31 |
Vector Tobacco Inc |
TOBACCO PRODUCTS WITH REDUCED RISKS AND PROCESS FOR PRODUCING THE SAME
|
US20090221670A1
(en)
|
2005-05-11 |
2009-09-03 |
Aarhus Universitet |
Method for diagnosis and treatment of a mental disease
|
WO2006127507A2
(en)
*
|
2005-05-20 |
2006-11-30 |
Integrated Dna Technologies, Inc. |
Compounds and methods for labeling oligonucleotides
|
BRPI0611514A2
(pt)
*
|
2005-05-25 |
2010-09-14 |
Tina Holding Aps |
formação estável e seletiva de estruturas trìplex e dúplex do tipo hoogsteen utilizando ácidos nucléicos torcidos e intercalados (tina) e processos para o preparo de tina
|
EP1883707B1
(en)
|
2005-05-26 |
2014-04-09 |
Human Genetic Signatures PTY Ltd |
Isothermal strand displacement amplification using primers containing a non-regular base
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US7745122B2
(en)
|
2005-07-15 |
2010-06-29 |
Applied Biosystems, Llc |
Analyzing messenger RNA and micro RNA in the same reaction mixture
|
EP1910397A4
(en)
|
2005-07-15 |
2009-07-01 |
Applera Corp |
DESIGNED A HOT START TRANSFER THROUGH PRIMER
|
US20100015604A1
(en)
|
2005-08-17 |
2010-01-21 |
Evriklia Lianidou |
Composition and method for determination of ck19 expression
|
EP2338992A3
(en)
|
2005-08-29 |
2011-10-12 |
Regulus Therapeutics, Inc |
Antisense compounds having enhanced anti-microRNA activity
|
WO2007026823A1
(ja)
*
|
2005-08-31 |
2007-03-08 |
Osaka University |
人工核酸プローブを用いた三重鎖核酸形成を基盤とした標的核酸の検出
|
US20070059713A1
(en)
|
2005-09-09 |
2007-03-15 |
Lee Jun E |
SSB-DNA polymerase fusion proteins
|
US8343738B2
(en)
|
2005-09-14 |
2013-01-01 |
Human Genetic Signatures Pty. Ltd. |
Assay for screening for potential cervical cancer
|
WO2007041201A2
(en)
|
2005-10-03 |
2007-04-12 |
Applera Corporation |
Compositions, methods, and kits for amplifying nucleic acids
|
JP5623016B2
(ja)
|
2005-12-01 |
2014-11-12 |
プロネイ・セラピューティクス・インコーポレイテッドPronaitherapeutics, Inc. |
癌治療法およびそれに用いる医薬組成物
|
WO2007067907A1
(en)
|
2005-12-06 |
2007-06-14 |
Ambion, Inc. |
Reverse transcription primers and methods of design
|
WO2007073149A1
(en)
|
2005-12-22 |
2007-06-28 |
Keygene N.V. |
Alternative nucleotides for improved targeted nucleotide exchange
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
AU2007211080B9
(en)
|
2006-01-27 |
2012-05-03 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
EP1984499B1
(en)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
BRPI0707276B1
(pt)
|
2006-01-27 |
2021-08-31 |
Biogen Ma Inc |
Polipeptídeo de fusão antagonista de receptor nogo
|
WO2007106690A2
(en)
|
2006-03-15 |
2007-09-20 |
Siemens Healthcare Diagnostics Inc. |
Degenerate nucleobase analogs
|
CN101448957A
(zh)
|
2006-03-16 |
2009-06-03 |
潘塔贝斯公司 |
用于检测核酸、核酸的甲基化状态和突变体的包含信号对和疏水性核苷酸、无茎信标的寡核苷酸
|
AU2007229161B2
(en)
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
KR101407707B1
(ko)
|
2006-04-03 |
2014-06-19 |
산타리스 팔마 에이/에스 |
Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
|
CN102851291B
(zh)
|
2006-04-03 |
2016-03-09 |
斯特拉有限责任公司 |
包含抗微小rna反义寡核苷酸的药物组合物
|
AU2007248483A1
(en)
|
2006-05-03 |
2007-11-15 |
Geisinger Clinic |
Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
|
AU2007257094B2
(en)
|
2006-05-05 |
2012-10-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of SGLT2
|
EP2505650A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
US7547684B2
(en)
*
|
2006-05-11 |
2009-06-16 |
Isis Pharmaceuticals, Inc. |
5′-modified bicyclic nucleic acid analogs
|
CA2659301A1
(en)
|
2006-07-28 |
2008-02-07 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
EP2484781B1
(en)
|
2006-08-01 |
2017-08-23 |
Applied Biosystems, LLC |
Detection of analytes and nucleic acids
|
JP5560039B2
(ja)
|
2006-10-05 |
2014-07-23 |
マサチューセッツ インスティテュート オブ テクノロジー |
ハイスループット分析のための多機能のコード化された粒子
|
DK2092065T4
(da)
|
2006-10-18 |
2019-10-21 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser
|
WO2008046911A2
(en)
|
2006-10-20 |
2008-04-24 |
Exiqon A/S |
Novel human micrornas associated with cancer
|
EP2407558A1
(en)
|
2006-10-31 |
2012-01-18 |
Noxxon Pharma AG |
Methods for the detection of a single- or double-stranded nucleic acid molecule
|
EP2094832B1
(en)
|
2006-11-15 |
2015-04-22 |
The J. David Gladstone Institutes |
Methods and compositions for reducing amyloid beta levels
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
MX2009005527A
(es)
|
2006-11-27 |
2009-06-08 |
Isis Pharmaceuticals Inc |
Metodos para el tratamiento de hipercolesterolemia.
|
US8293684B2
(en)
|
2006-11-29 |
2012-10-23 |
Exiqon |
Locked nucleic acid reagents for labelling nucleic acids
|
EP2113567B1
(en)
|
2006-12-21 |
2019-04-03 |
QIAGEN GmbH |
MicroRNA target site blocking oligos and uses thereof
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
WO2009045469A2
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
MX2009008470A
(es)
|
2007-02-09 |
2009-11-26 |
Univ Northwestern |
Particulas para detectar objetivos intracelulares.
|
EP2126079A1
(en)
|
2007-03-22 |
2009-12-02 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
WO2008113832A2
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
|
JP2010522245A
(ja)
|
2007-03-24 |
2010-07-01 |
ゲンザイム コーポレイション |
ヒトアポリポタンパク質bと相補的なアンチセンスオリゴヌクレオチドの投与
|
US8999634B2
(en)
|
2007-04-27 |
2015-04-07 |
Quest Diagnostics Investments Incorporated |
Nucleic acid detection combining amplification with fragmentation
|
CA2687291A1
(en)
|
2007-05-16 |
2008-11-20 |
Ktb Tumorforschungsgesellschaft Mbh |
Low-viscous anthracycline formulation
|
EP2826863B1
(en)
|
2007-05-30 |
2017-08-23 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
CA2688321A1
(en)
*
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
WO2008151023A2
(en)
|
2007-06-01 |
2008-12-11 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
US7807372B2
(en)
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
EP2173373B1
(en)
|
2007-06-06 |
2020-04-15 |
Sarepta Therapeutics, Inc. |
Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
ES2376507T5
(es)
†
|
2007-07-05 |
2015-08-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos 6-disustituidos
|
AU2008282780B2
(en)
|
2007-08-01 |
2014-04-17 |
Dana- Farber Cancer Institute |
Enrichment of a target sequence
|
AU2008286771B2
(en)
|
2007-08-15 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP2183360B1
(en)
|
2007-08-30 |
2017-01-11 |
Hadasit Medical Research Services&Development Company Ltd. |
Nucleic acid sequences comprising nf-(kappa)b binding site within o(6)-methylguanine-dna-methyltransferase (mgmt) promoter region and uses thereof for the treatment of cancer and immune-related disorders
|
WO2009039173A2
(en)
|
2007-09-19 |
2009-03-26 |
Applied Biosystems Inc. |
SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
|
RU2487716C2
(ru)
|
2007-10-03 |
2013-07-20 |
Кварк Фармасьютикалс, Инк. |
Новые структуры малых интерферирующих рнк (sirna)
|
CN101821391B
(zh)
|
2007-10-04 |
2016-04-27 |
桑塔里斯制药公司 |
微小聚体
|
CA2705213C
(en)
|
2007-11-07 |
2016-10-04 |
The University Of British Columbia |
Microfluidic device and method of using same
|
JP2011502514A
(ja)
|
2007-11-09 |
2011-01-27 |
アイシス ファーマシューティカルズ インコーポレイティッド |
第7因子発現の調節
|
US20110059895A1
(en)
|
2007-11-09 |
2011-03-10 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 9 expression
|
US8017338B2
(en)
|
2007-11-20 |
2011-09-13 |
Life Technologies Corporation |
Reversible di-nucleotide terminator sequencing
|
CA2706740C
(en)
|
2007-11-27 |
2017-01-17 |
Human Genetic Signatures Pty Ltd |
Enzymes for amplification and copying bisulphite modified nucleic acids
|
ES2916498T3
(es)
|
2007-12-06 |
2022-07-01 |
Genalyte Inc |
Método para identificar una secuencia de nucleótidos en una especie desconocida de ácido nucleico; y dispositivo para llevar a cabo el método
|
US8404659B2
(en)
|
2008-03-07 |
2013-03-26 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of MicroRNA related diseases
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
EP2282744B1
(en)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
CA2720473A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of epas1 inhibitors
|
US8278287B2
(en)
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
AU2009237577B2
(en)
|
2008-04-18 |
2014-06-05 |
Baxter Healthcare Sa |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
US8541388B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of RBP4
|
WO2009143387A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Modulation of smrt expression
|
ES2610588T3
(es)
|
2008-05-27 |
2017-04-28 |
Dako Denmark A/S |
Composiciones y métodos para la detección de aberraciones cromosómicas con tampones de hibridación novedosos
|
WO2009149182A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
JP5524189B2
(ja)
|
2008-06-06 |
2014-06-18 |
クォーク ファーマシューティカルズ インコーポレーティッド |
耳障害治療のための組成物および方法
|
JP2011529686A
(ja)
|
2008-07-29 |
2011-12-15 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ポリグルタミンタンパク質発現の選択的阻害
|
CA2735250A1
(en)
*
|
2008-07-30 |
2010-02-04 |
Nippon Steel Kankyo Engineering Co., Ltd. |
Universal nucleic acid probe set and method for utilization thereof
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
JP5357883B2
(ja)
*
|
2008-08-22 |
2013-12-04 |
独立行政法人科学技術振興機構 |
新規核酸誘導体およびそれを用いたヌクレアーゼ耐性核酸の調製方法
|
WO2010027831A1
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
EP2331141B1
(en)
|
2008-08-25 |
2016-01-06 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
US8583380B2
(en)
|
2008-09-05 |
2013-11-12 |
Aueon, Inc. |
Methods for stratifying and annotating cancer drug treatment options
|
DK2361256T3
(da)
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
EP3335715A3
(en)
|
2008-10-15 |
2018-08-08 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
WO2010062627A2
(en)
|
2008-10-27 |
2010-06-03 |
Genalyte Inc. |
Biosensors based on optical probing and sensing
|
EP2365803B1
(en)
|
2008-11-24 |
2017-11-01 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
KR20110091796A
(ko)
|
2008-12-04 |
2011-08-12 |
오피케이오 큐알엔에이, 엘엘씨 |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
EP2370579B1
(en)
|
2008-12-04 |
2017-03-29 |
CuRNA, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
MX2011005912A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
JP2012513199A
(ja)
|
2008-12-22 |
2012-06-14 |
キージーン・エン・フェー |
植物プロトプラストにおける標的化遺伝子改変の効率を増大させるための二本鎖rnaの使用
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
WO2010083338A2
(en)
|
2009-01-14 |
2010-07-22 |
Philadelphia Health And Education Corporation |
Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
|
CN102301011B
(zh)
|
2009-02-02 |
2014-05-07 |
埃克西库恩公司 |
对小rna进行定量的方法
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
KR101682735B1
(ko)
|
2009-02-12 |
2016-12-06 |
큐알엔에이, 인크. |
뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료
|
WO2010097655A1
(en)
|
2009-02-26 |
2010-09-02 |
Dako Denmark A/S |
Compositions and methods for rna hybridization applications
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
US20120088814A1
(en)
|
2009-03-31 |
2012-04-12 |
Isis Pharmaceuticals, Inc. |
Methods of modulating an immune response to a viral infection
|
JP6145270B2
(ja)
|
2009-04-15 |
2017-06-07 |
ノースウェスタン ユニバーシティ |
オリゴヌクレオチド機能化ナノ粒子の送達
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
EP2421972A2
(en)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
EP2421970B1
(en)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CA2761152A1
(en)
|
2009-05-06 |
2010-11-11 |
Opko Curna, Llc |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
ES2618572T3
(es)
|
2009-05-08 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
|
KR101749356B1
(ko)
|
2009-05-18 |
2017-07-06 |
큐알엔에이, 인크. |
재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료
|
EP3150619B1
(en)
|
2009-05-21 |
2019-09-18 |
Siemens Healthcare Diagnostics Inc. |
Universal tags with non-natural nucleobases
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
EP2435571B1
(en)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
DK3276004T3
(da)
|
2009-06-08 |
2020-04-06 |
Quark Pharmaceuticals Inc |
Fremgangsmåder til behandling af kronisk nyresygdom
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
KR101801404B1
(ko)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
JP2011024434A
(ja)
|
2009-07-22 |
2011-02-10 |
Galaxy Pharma Inc |
オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー
|
JP2013500017A
(ja)
|
2009-07-24 |
2013-01-07 |
カッパーアールエヌエー,インコーポレイテッド |
サ−チュイン(sirt)への天然アンチセンス転写物の阻止によるサ−チュイン(sirt)関連疾患の治療
|
WO2011012136A1
(en)
|
2009-07-28 |
2011-02-03 |
Exiqon A/S |
A method for classifying a human cell sample as cancerous
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
JP6189594B2
(ja)
|
2009-08-11 |
2017-08-30 |
クルナ・インコーポレーテッド |
アディポネクチン(adipoq)に対する天然アンチセンス転写物の抑制によるアディポネクチン(adipoq)関連疾患の治療
|
EP2982755B1
(en)
|
2009-08-21 |
2020-10-07 |
CuRNA, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
EP2470657B1
(en)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
CA2773886C
(en)
|
2009-09-11 |
2018-01-09 |
Isis Pharmaceuticals, Inc. |
Modulation of huntingtin expression
|
NO2480669T3
(xx)
|
2009-09-25 |
2018-04-07 |
|
|
EP2488656B1
(en)
|
2009-10-15 |
2015-06-03 |
Ibis Biosciences, Inc. |
Multiple displacement amplification
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
US20110129832A1
(en)
|
2009-10-27 |
2011-06-02 |
Swift Biosciences, Inc. |
Polynucleotide Primers and Probes
|
JP5866119B2
(ja)
|
2009-10-30 |
2016-02-17 |
ノースウェスタン ユニバーシティ |
鋳型ナノ複合体
|
US20110110860A1
(en)
|
2009-11-02 |
2011-05-12 |
The Board Of Regents Of The University Of Texas System |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
WO2011056215A1
(en)
|
2009-11-03 |
2011-05-12 |
Landers James P |
Versatile, visible method for detecting polymeric analytes
|
JP2013511285A
(ja)
|
2009-11-23 |
2013-04-04 |
スイフト・バイオサイエンシズ・インコーポレイテツド |
一本鎖標的分子を伸長させるデバイス
|
NZ599707A
(en)
|
2009-11-30 |
2014-07-25 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
ES2601237T3
(es)
|
2009-12-02 |
2017-02-14 |
Dako Denmark A/S |
Composiciones y métodos para realizar hibridaciones sin desnaturalización
|
US8778904B2
(en)
|
2009-12-09 |
2014-07-15 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the CNS
|
CN102741410B
(zh)
|
2009-12-09 |
2016-11-16 |
日东电工株式会社 |
Hsp47表达的调节
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
RU2609631C2
(ru)
|
2009-12-23 |
2017-02-02 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
CN102770540B
(zh)
|
2009-12-29 |
2017-06-23 |
库尔纳公司 |
通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
|
US20120289583A1
(en)
|
2009-12-31 |
2012-11-15 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
WO2011085271A2
(en)
|
2010-01-08 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
CA2789005A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
JP6018506B2
(ja)
|
2010-02-08 |
2016-11-02 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
対立遺伝子多様体の選択的低減
|
KR101838308B1
(ko)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료
|
WO2011106297A2
(en)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
EP2542678B1
(en)
|
2010-03-04 |
2017-04-12 |
InteRNA Technologies B.V. |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
|
US8623603B2
(en)
|
2010-03-08 |
2014-01-07 |
Dana-Farber Cancer Institute, Inc. |
Full cold-PCR enrichment with reference blocking sequence
|
WO2011113054A2
(en)
|
2010-03-12 |
2011-09-15 |
Aurasense Llc |
Crosslinked polynucleotide structure
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
WO2011120049A1
(en)
|
2010-03-26 |
2011-09-29 |
Integrated Dna Technologies, Inc. |
Methods for enhancing nucleic acid hybridization
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
RU2612884C2
(ru)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
US8993738B2
(en)
|
2010-04-28 |
2015-03-31 |
Isis Pharmaceuticals, Inc. |
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
PT2563920T
(pt)
|
2010-04-29 |
2017-05-26 |
Ionis Pharmaceuticals Inc |
Modulação da expressão de transtirretina
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
DK2563935T3
(da)
|
2010-04-30 |
2014-06-23 |
Exiqon As |
In situ-hybridiseringsfremgangsmåde og -buffer
|
US9089588B2
(en)
|
2010-05-03 |
2015-07-28 |
Curna, Inc. |
Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
RU2620978C2
(ru)
|
2010-05-26 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011156432A2
(en)
|
2010-06-07 |
2011-12-15 |
Firefly Bioworks, Inc. |
Scanning multifunctional particles
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR MODULATING THE INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
PL2585596T3
(pl)
|
2010-06-23 |
2021-06-28 |
Curna, Inc. |
Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
|
JPWO2012002477A1
(ja)
|
2010-06-30 |
2013-08-29 |
三菱化学メディエンス株式会社 |
高感度な変異遺伝子の検出方法
|
NZ704322A
(en)
|
2010-07-06 |
2016-07-29 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
EP2593547B1
(en)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
CA2803011C
(en)
|
2010-07-16 |
2019-12-03 |
Tocagen Inc. |
Retrovirus detection
|
CN106434648A
(zh)
|
2010-07-19 |
2017-02-22 |
F·C·贝内特 |
肌强直性营养障碍蛋白激酶(dmpk)表达的调节
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
US9243246B2
(en)
|
2010-08-24 |
2016-01-26 |
Sirna Therapeutics, Inc. |
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
|
AU2011299233B2
(en)
|
2010-09-07 |
2016-09-15 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
ES2701020T3
(es)
|
2010-09-22 |
2019-02-20 |
Alios Biopharma Inc |
Nucleósidos azido y análogos nucleotídicos
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
US9921165B2
(en)
|
2010-11-05 |
2018-03-20 |
Genalyte, Inc. |
Optical analyte detection systems and methods of use
|
US9150864B2
(en)
|
2010-11-08 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
JP6126009B2
(ja)
*
|
2010-11-17 |
2017-05-10 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
α−シヌクレイン発現の調節
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
CN103502449B
(zh)
|
2010-12-02 |
2016-08-10 |
关键基因股份有限公司 |
用寡核苷酸靶向改变dna
|
ES2588482T3
(es)
|
2010-12-02 |
2016-11-03 |
Keygene N.V. |
Alteración dirigida de ADN
|
MX2017015093A
(es)
|
2011-01-11 |
2023-03-10 |
Seegene Inc |
Detección de secuencias de ácido nucleico objetivo mediante ensayo de escisión y extensión del pto.
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
BR112013019803A2
(pt)
|
2011-02-02 |
2019-06-11 |
Excaliard Pharmaceuticals Inc |
método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)
|
DK2670404T3
(en)
|
2011-02-02 |
2018-11-19 |
Univ Princeton |
CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
|
EP3067421B1
(en)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
US20140044644A1
(en)
|
2011-02-21 |
2014-02-13 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
SG10201604479YA
(en)
|
2011-03-03 |
2016-07-28 |
Quark Pharmaceuticals Inc |
Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
AU2012223365B2
(en)
|
2011-03-03 |
2016-11-10 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
ES2472965T3
(es)
|
2011-03-04 |
2014-07-03 |
F. Hoffmann-La Roche Ag |
Nuevo tipo de sondas universales para la detección de variantes gen�micas
|
WO2012134195A2
(en)
|
2011-03-29 |
2012-10-04 |
Seegene, Inc. |
Detection of target nucleic acid sequence by pto cleavage and extension-dependent cleavage
|
EP3333269B1
(en)
|
2011-03-31 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Methods to enable multiplex cold-pcr
|
CN107012144A
(zh)
|
2011-04-01 |
2017-08-04 |
Ionis制药公司 |
信号转导及转录激活蛋白3(stat3)表达的调节
|
EP2508607A1
(en)
|
2011-04-07 |
2012-10-10 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for liver regeneration and for treatment of liver failure
|
JP5951752B2
(ja)
|
2011-04-13 |
2016-07-13 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Ptp1b発現のアンチセンス調節
|
SI3505528T1
(sl)
|
2011-04-21 |
2021-04-30 |
Glaxo Group Limited |
Modulacija izražanja virusa hepatitisa B (HBV)
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
KR20190062511A
(ko)
|
2011-04-27 |
2019-06-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지방단백질 ciii (apociii) 발현의 조정
|
US8450061B2
(en)
|
2011-04-29 |
2013-05-28 |
Sequenom, Inc. |
Quantification of a minority nucleic acid species
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
MX342067B
(es)
|
2011-05-04 |
2016-09-09 |
Seegene Inc |
Detección de secuencias de ácido nucleico objetivo por desdoblamiento e hibridización de oligonucleótido de sonda.
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP3320922A1
(en)
|
2011-06-10 |
2018-05-16 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
WO2012170947A2
(en)
|
2011-06-10 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
EP2721156B1
(en)
|
2011-06-16 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
AU2012275096B2
(en)
|
2011-06-29 |
2016-02-04 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
WO2013022966A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
DK2751270T3
(en)
|
2011-08-29 |
2018-10-29 |
Ionis Pharmaceuticals Inc |
OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
|
US9650421B2
(en)
|
2011-09-02 |
2017-05-16 |
Northwestern University |
Self-assembled nanostructures
|
EA029151B1
(ru)
|
2011-09-06 |
2018-02-28 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
|
US9732375B2
(en)
|
2011-09-07 |
2017-08-15 |
Human Genetic Signatures Pty. Ltd. |
Molecular detection assay using direct treatment with a bisulphite reagent
|
EP2755692B1
(en)
|
2011-09-14 |
2020-11-25 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
CA2849273C
(en)
|
2011-09-20 |
2020-07-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gcgr expression
|
EP2761028A1
(en)
|
2011-09-30 |
2014-08-06 |
Dako Denmark A/S |
Hybridization compositions and methods using formamide
|
EP2768974B1
(en)
|
2011-10-21 |
2017-07-19 |
Dako Denmark A/S |
Hybridization compositions and methods
|
AU2012328680A1
(en)
|
2011-10-25 |
2014-05-01 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of GCCR expression
|
EP2773758B1
(en)
|
2011-11-03 |
2017-06-07 |
Quark Pharmaceuticals, Inc. |
Compositions for use in neuroprotection
|
EP2776564B1
(en)
|
2011-11-07 |
2019-10-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of tmprss6 expression
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
CA2859581C
(en)
|
2011-12-16 |
2022-03-22 |
National University Corporation Tokyo Medical And Dental University |
Chimeric double-stranded nucleic acid
|
ES2886147T3
(es)
|
2011-12-22 |
2021-12-16 |
Interna Tech B V |
MiARN para el tratamiento del cáncer de cabeza y de cuello
|
JP6280045B2
(ja)
|
2011-12-22 |
2018-02-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
肺腺癌内転移関連性転写物1(metastasis−associated−in−lung−adenocarcinoma−transcript−1:malat−1)の発現調節法
|
US9073960B2
(en)
*
|
2011-12-22 |
2015-07-07 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9562072B2
(en)
|
2011-12-27 |
2017-02-07 |
The J. David Gladstone Institutes |
Compositions and methods for regulating glucose metabolism
|
ES2842938T3
(es)
|
2012-01-11 |
2021-07-15 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para la modulación del empalme de IKBKAP
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
KR101794981B1
(ko)
|
2012-03-05 |
2017-11-09 |
주식회사 씨젠 |
Pto 절단 및 연장 어세이에 의한 타겟 핵산서열에서의 뉴클레오타이드 변이 검출
|
EP3907506A1
(en)
|
2012-03-12 |
2021-11-10 |
The Board of Trustees of the University of Illinois |
Optical analyte detection systems with magnetic enhancement and methods of their use
|
SG11201405669XA
(en)
|
2012-03-13 |
2014-10-30 |
Swift Biosciences Inc |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
DK2825648T3
(en)
|
2012-03-15 |
2018-10-15 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
US9340784B2
(en)
|
2012-03-19 |
2016-05-17 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
AU2013202595B2
(en)
|
2012-03-30 |
2016-04-21 |
Biogen Ma Inc. |
Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2013154798A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
EP3336189A1
(en)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US9133490B2
(en)
|
2012-05-16 |
2015-09-15 |
Transgenomic, Inc. |
Step-up method for COLD-PCR enrichment
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
WO2013177248A2
(en)
|
2012-05-22 |
2013-11-28 |
Isis Pharmaceuticals, Inc. |
Modulation of enhancer rna mediated gene expression
|
RU2748495C2
(ru)
|
2012-05-24 |
2021-05-26 |
Ионис Фармасьютикалз, Инк. |
Способы и композиции для модулирования экспрессии аполипопротеина (а)
|
DK2800811T3
(en)
|
2012-05-25 |
2017-07-17 |
Univ Vienna |
METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
|
EP2861611B1
(en)
|
2012-05-25 |
2016-07-13 |
Janssen Sciences Ireland UC |
Uracyl spirooxetane nucleosides
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
ES2688831T3
(es)
|
2012-06-25 |
2018-11-07 |
Ionis Pharmaceuticals, Inc. |
Modulación de la expresión de UBE3A-ATS
|
WO2014015098A1
(en)
|
2012-07-18 |
2014-01-23 |
Siemens Healthcare Diagnostics Inc. |
A method of normalizing biological samples
|
WO2014018930A1
(en)
|
2012-07-27 |
2014-01-30 |
Isis Pharmaceuticals. Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
EP2885312A4
(en)
|
2012-08-15 |
2016-01-20 |
Isis Pharmaceuticals Inc |
PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS USING MODIFIED STREAMING PROTOCOLS
|
EP2890704B1
(en)
|
2012-08-31 |
2018-02-28 |
Novartis AG |
2'-ethynyl nucleoside derivatives for treatment of viral infections
|
WO2014039916A1
(en)
|
2012-09-06 |
2014-03-13 |
The University Of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
WO2014059364A1
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
WO2014059356A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
EP2906258A4
(en)
|
2012-10-15 |
2016-08-10 |
Ionis Pharmaceuticals Inc |
COMPOSITIONS FOR MODULATING THE EXPRESSION OF C90RF72
|
EP2906697A4
(en)
|
2012-10-15 |
2016-06-22 |
Ionis Pharmaceuticals Inc |
METHODS OF MONITORING C9ORF72 EXPRESSION
|
EP2906696B2
(en)
|
2012-10-15 |
2022-12-14 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating c9orf72 expression
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2920308B1
(en)
|
2012-10-31 |
2018-12-12 |
Ionis Pharmaceuticals, Inc. |
Cancer treatment
|
KR20150087270A
(ko)
|
2012-11-05 |
2015-07-29 |
프로나이 테라퓨틱스, 인코포레이티드 |
Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
|
US10201556B2
(en)
|
2012-11-06 |
2019-02-12 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
|
EP2920304B1
(en)
|
2012-11-15 |
2019-03-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
RU2015120645A
(ru)
|
2012-11-26 |
2017-01-10 |
Рош Инновейшен Сентер Копенгаген А/С |
Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3)
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
RS61767B1
(sr)
|
2012-12-21 |
2021-05-31 |
Janssen Biopharma Inc |
4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv
|
EP2943570B1
(en)
|
2013-01-14 |
2018-01-03 |
Pierfrancesco Tassone |
Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma
|
EP2946013A1
(en)
|
2013-01-16 |
2015-11-25 |
Iowa State University Research Foundation, Inc. |
A deep intronic target for splicing correction on spinal muscular atrophy gene
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
EP2951305B1
(en)
|
2013-01-30 |
2018-08-15 |
F.Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
US9701708B2
(en)
|
2013-01-31 |
2017-07-11 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
KR20200123263A
(ko)
|
2013-02-14 |
2020-10-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
|
ES2662825T3
(es)
|
2013-02-25 |
2018-04-09 |
Seegene, Inc. |
Detección de variación de nucleótido en una secuencia de ácidos nucleicos diana
|
US10086093B2
(en)
|
2013-02-28 |
2018-10-02 |
The General Hospital Corporation |
miRNA profiling compositions and methods of use
|
EP2961853B1
(en)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
EP2961841B1
(en)
|
2013-03-01 |
2020-01-22 |
National University Corporation Tokyo Medical and Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
KR101943623B1
(ko)
|
2013-03-13 |
2019-01-30 |
주식회사 씨젠 |
멜팅 피크 분석을 이용한 타겟 핵산서열의 정량
|
EP2971098B1
(en)
|
2013-03-14 |
2018-11-21 |
Translate Bio, Inc. |
Quantitative assessment for cap efficiency of messenger rna
|
US9644207B2
(en)
|
2013-03-14 |
2017-05-09 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Tau expression
|
AU2014239250A1
(en)
|
2013-03-14 |
2015-08-27 |
Shire Human Genetic Therapies, Inc. |
Quantitative assessment for cap efficiency of messenger RNA
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
WO2014143637A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for enhancing immunoassays
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
US9840533B2
(en)
|
2013-04-29 |
2017-12-12 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
EP2992098B1
(en)
|
2013-05-01 |
2019-03-27 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating hbv and ttr expression
|
CA2913499A1
(en)
|
2013-05-30 |
2014-12-04 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded agents for delivering therapeutic oligonucleotides
|
AU2014280847B2
(en)
|
2013-06-13 |
2019-07-04 |
Antisense Therapeutics Ltd |
Combination therapy
|
WO2014203518A1
(en)
|
2013-06-16 |
2014-12-24 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded antisense nucleic acid with exon-skipping effect
|
WO2014205449A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
|
SG10201908122XA
(en)
|
2013-06-27 |
2019-10-30 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
MX2015017863A
(es)
|
2013-07-02 |
2016-11-30 |
Ionis Pharmaceuticals Inc |
Moduladores de receptor de hormona de crecimiento.
|
JP6050555B2
(ja)
|
2013-07-15 |
2016-12-21 |
シージーン アイエヌシー |
Ptoの切断及び延長−依存的固定化オリゴヌクレオチドハイブリダイゼーションを用いたターゲット核酸配列の検出
|
JP6617702B2
(ja)
|
2013-07-15 |
2019-12-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Fty720のアザサイクリック拘束アナログ
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
HUE048710T2
(hu)
|
2013-08-08 |
2020-08-28 |
Scripps Research Inst |
Eljárás nukleinsavak in vitro helyspecifikus enzimes jelölésére nem-természetes nukleotidok beépítésével
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
WO2015031679A2
(en)
|
2013-08-28 |
2015-03-05 |
Isis Pharmaceuticals, Inc. |
Modulation of prekallikrein (pkk) expression
|
CN105744959B
(zh)
|
2013-09-13 |
2020-12-01 |
Ionis制药公司 |
补体因子b的调节剂
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
KR20220159478A
(ko)
|
2013-10-04 |
2022-12-02 |
알닐람 파마슈티칼스 인코포레이티드 |
Alas1 유전자의 발현을 억제하기 위한 조성물 및 방법
|
WO2015054676A2
(en)
|
2013-10-11 |
2015-04-16 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
CN105813721B
(zh)
|
2013-10-16 |
2019-11-05 |
不列颠哥伦比亚大学 |
用于以小体积配制颗粒的装置
|
WO2015057008A2
(en)
|
2013-10-18 |
2015-04-23 |
Seegene, Inc. |
Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay
|
WO2015061246A1
(en)
|
2013-10-21 |
2015-04-30 |
Isis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
WO2015071474A2
(en)
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
CN112107693B
(zh)
|
2013-12-03 |
2023-05-26 |
西北大学 |
脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
WO2015089277A1
(en)
|
2013-12-12 |
2015-06-18 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
CA2931510A1
(en)
|
2013-12-24 |
2015-07-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
EP3099798B1
(en)
|
2014-01-29 |
2018-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
ES2694857T3
(es)
|
2014-02-04 |
2018-12-27 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
JP6594902B2
(ja)
|
2014-02-11 |
2019-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物及びその使用方法
|
EP2907874A1
(en)
|
2014-02-14 |
2015-08-19 |
Université de Lausanne |
MiR-21-3p inhibitors in skin disorders
|
EP3119789B1
(en)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
EP3978610A3
(en)
|
2014-03-19 |
2022-08-24 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
JP6622214B2
(ja)
|
2014-04-01 |
2019-12-18 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Sod−1発現を調節するための組成物
|
EP3129493B1
(en)
|
2014-04-09 |
2021-07-07 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
KR102369736B1
(ko)
|
2014-05-01 |
2022-03-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
보체 인자 b 발현을 조절하기 위한 조성물 및 방법
|
JP6667453B2
(ja)
|
2014-05-01 |
2020-03-18 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
成長ホルモン受容体発現を調節するための組成物及び方法
|
DK3137091T3
(da)
|
2014-05-01 |
2021-01-25 |
Ionis Pharmaceuticals Inc |
Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
|
BR122020024443B1
(pt)
|
2014-05-01 |
2022-02-22 |
Ionis Pharmaceuticals, Inc |
Composto e composição farmacêutica para modulação da expressão de angptl3
|
EP4223315A3
(en)
|
2014-05-01 |
2023-08-23 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
AU2015264038B2
(en)
|
2014-05-22 |
2021-02-11 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
|
EP3508198A1
(en)
|
2014-06-04 |
2019-07-10 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
EP4039807A1
(en)
|
2014-06-10 |
2022-08-10 |
Erasmus University Rotterdam Medical Center |
Antisense oligonucleotides useful in treatment of pompe disease
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
JP6562517B2
(ja)
*
|
2014-07-31 |
2019-08-21 |
国立大学法人大阪大学 |
架橋型ヌクレオシドおよびヌクレオチド
|
AU2015305482B2
(en)
|
2014-08-19 |
2021-04-01 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
IL234246A0
(en)
|
2014-08-21 |
2014-11-30 |
Omrix Biopharmaceuticals Ltd |
Stabilized thrombin
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
EP3189141B1
(en)
|
2014-09-02 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Antisense oligonucleotides targeting 3'utr region of a20
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
EA201790642A1
(ru)
|
2014-09-18 |
2017-09-29 |
Ти Юниверсити Оф Бритиш Коламбиа |
Аллель-специфическая терапия для гаплотипов болезни хантингтона
|
SG11201702074VA
(en)
|
2014-09-29 |
2017-04-27 |
Jackson Lab |
High efficiency, high throughput generation of genetically modified mammals by electroporation
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
WO2016061131A1
(en)
|
2014-10-14 |
2016-04-21 |
The J. David Gladstone Institutes |
Compositions and methods for reactivating latent immunodeficiency virus
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
KR20170083108A
(ko)
|
2014-11-10 |
2017-07-17 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
C형 간염에 대한 장기 작용 약학적 조성물
|
KR20170081257A
(ko)
|
2014-11-10 |
2017-07-11 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
C형 간염에 대한 조합 장기 작용 조성물 및 방법
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
CA2968531A1
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
WO2016086104A1
(en)
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
US20180355413A1
(en)
|
2014-12-22 |
2018-12-13 |
Anapa Biotech A/S |
Dual quenching assay for multiplex detection of target nucleic acids
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
AU2016219263B2
(en)
|
2015-02-13 |
2022-12-01 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
|
ES2848377T3
(es)
|
2015-02-26 |
2021-08-09 |
Ionis Pharmaceuticals Inc |
Moduladores específicos de alelo de RODOPSINA P23H
|
EP3265564B1
(en)
|
2015-03-03 |
2022-01-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating mecp2 expression
|
EP3265098A4
(en)
|
2015-03-03 |
2019-02-13 |
Ionis Pharmaceuticals, Inc. |
COMPOSITIONS FOR MODULATING MECP2 EXPRESSION
|
US10415038B2
(en)
|
2015-04-03 |
2019-09-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating TMPRSS6 expression
|
TN2017000427A1
(en)
|
2015-04-08 |
2019-04-12 |
Univ Northwestern |
Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP3283631A1
(en)
|
2015-04-13 |
2018-02-21 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
SG11201708468YA
(en)
|
2015-04-16 |
2017-11-29 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
EP3324980B1
(en)
|
2015-07-17 |
2021-11-10 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
EP3331536A4
(en)
|
2015-08-03 |
2019-03-27 |
The Regents of The University of California |
COMPOSITIONS AND METHODS FOR MODULATING ABHD2 ACTIVITY
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
KR20180051550A
(ko)
|
2015-09-02 |
2018-05-16 |
알닐람 파마슈티칼스 인코포레이티드 |
프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
US10988810B2
(en)
|
2015-09-14 |
2021-04-27 |
Pentabase Aps |
Methods and materials for detection of mutations
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
TW201718618A
(zh)
*
|
2015-09-18 |
2017-06-01 |
田邊三菱製藥股份有限公司 |
架橋型核酸GuNA,其製造方法,及中間體化合物
|
US20190048340A1
(en)
|
2015-09-24 |
2019-02-14 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
CA2999177A1
(en)
|
2015-09-24 |
2017-03-30 |
The Regents Of The University Of California |
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
|
EP4285912A3
(en)
|
2015-09-25 |
2024-07-10 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
CA2998898A1
(en)
|
2015-10-08 |
2017-04-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
IL308174A
(en)
|
2015-10-09 |
2024-01-01 |
Univ Southampton |
Gene expression modulation and dysregulated protein expression scanning
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
US20190225644A1
(en)
|
2015-10-16 |
2019-07-25 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
EP3183347A4
(en)
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
JP7023842B2
(ja)
|
2015-10-29 |
2022-02-22 |
テンプル ユニヴァーシティ - オブ ザ コモンウェルス システム オブ ハイアー エデュケーション |
Dnaポリメラーゼシータによる核酸の3’末端の修飾
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
WO2017079745A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
BR122023026882A2
(pt)
|
2015-11-06 |
2024-01-23 |
Ionis Pharmaceuticals, Inc |
Uso de um composto oligomérico
|
EP3374498A1
(en)
|
2015-11-12 |
2018-09-19 |
H. Hoffnabb-La Roche Ag |
Standardized neuronal cell assays from primate species
|
EP3380613B1
(en)
|
2015-11-23 |
2022-10-26 |
The Regents of the University of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
IL259795B2
(en)
|
2015-12-07 |
2024-04-01 |
Genzyme Corp |
Methods and preparations for the treatment of diseases related to SERPINC1
|
CA3007152A1
(en)
|
2015-12-07 |
2017-06-15 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
WO2017098468A1
(en)
|
2015-12-09 |
2017-06-15 |
Novartis Ag |
Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
EP3390636B1
(en)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
EP3797860A1
(en)
|
2016-01-06 |
2021-03-31 |
The University of British Columbia |
Bifurcating mixers and methods of their use and manufacture
|
JP2019501659A
(ja)
|
2016-01-15 |
2019-01-24 |
ザ ジャクソン ラボラトリー |
Cas9タンパク質のマルチサイクルエレクトロポレーションによる遺伝子修飾非ヒト哺乳動物
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3418289A4
(en)
|
2016-02-17 |
2019-10-30 |
Tokyo Institute of Technology |
ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
|
WO2017147483A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplexed single molecule rna visualization with a two-probe proximity ligation system
|
AU2017229778A1
(en)
|
2016-03-09 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting PMP22 expression
|
RS61528B1
(sr)
|
2016-03-14 |
2021-04-29 |
Hoffmann La Roche |
Oligonukleotidi za smanjenje ekspresije pd-l1
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
CA3017532A1
(en)
|
2016-04-13 |
2017-10-19 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017188898A1
(en)
|
2016-04-29 |
2017-11-02 |
Nanyang Technological University |
G-quadruplex-containing antisense oligonucleotides
|
BR112018072362A2
(pt)
|
2016-05-06 |
2019-02-19 |
Ionis Pharmaceuticals, Inc. |
oligonucleotídeos conjugados a uma unidade de ligando do receptor glp-1 e seus usos
|
KR102639586B1
(ko)
|
2016-06-06 |
2024-02-23 |
애로우헤드 파마슈티컬스 인코포레이티드 |
5'-시클로-포스포네이트 변형된 뉴클레오티드
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
US11708614B2
(en)
|
2016-06-15 |
2023-07-25 |
Streck Llc |
Assays and methods for determining microbial resistance
|
US10337051B2
(en)
|
2016-06-16 |
2019-07-02 |
The Regents Of The University Of California |
Methods and compositions for detecting a target RNA
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
DK3475295T3
(da)
|
2016-06-24 |
2022-10-24 |
Scripps Research Inst |
Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
|
CN109415732B
(zh)
|
2016-07-01 |
2024-01-02 |
豪夫迈·罗氏有限公司 |
用于调节htra1表达的反义寡核苷酸
|
SG11201900238UA
(en)
|
2016-07-15 |
2019-02-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulation of smn2
|
WO2018024849A1
(en)
|
2016-08-03 |
2018-02-08 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
EP4101859A1
(en)
|
2016-09-02 |
2022-12-14 |
Dicerna Pharmaceuticals, Inc. |
4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
EP3538671A1
(en)
|
2016-11-11 |
2019-09-18 |
Roche Innovation Center Copenhagen A/S |
Therapeutic oligonucleotides capture and detection
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
WO2018111835A1
(en)
|
2016-12-12 |
2018-06-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
US11230709B2
(en)
|
2016-12-28 |
2022-01-25 |
National University Corporation Kobe University |
Therapeutic drug for Alport's syndrome
|
IL267959B2
(en)
|
2017-01-10 |
2024-07-01 |
Arrowhead Pharmaceuticals Inc |
Alpha-1 antitrypsin (AAT) RNAi agents, preparations containing AAT RNAi agents and their uses
|
WO2018130582A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
CN110337495B
(zh)
|
2017-02-06 |
2024-03-29 |
日产化学株式会社 |
单链寡核苷酸
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
EP3594346A4
(en)
|
2017-03-10 |
2020-12-16 |
National Center For Child Health And Development |
ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
WO2018181428A1
(ja)
|
2017-03-29 |
2018-10-04 |
塩野義製薬株式会社 |
核酸医薬及び多分岐脂質の複合体
|
SG11201909572QA
(en)
|
2017-04-18 |
2019-11-28 |
Alnylam Pharmaceuticals Inc |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
CN110869498A
(zh)
|
2017-05-10 |
2020-03-06 |
加利福尼亚大学董事会 |
经由核递送crispr/cas9导向编辑细胞rna
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
US11401519B2
(en)
|
2017-06-07 |
2022-08-02 |
University Of Massachusetts |
Anti-ADAM33 oligonucleotides and related methods
|
US20200131555A1
(en)
|
2017-07-11 |
2020-04-30 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
KR20200028997A
(ko)
|
2017-07-13 |
2020-03-17 |
노오쓰웨스턴 유니버시티 |
올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
|
WO2019023243A1
(en)
|
2017-07-24 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE
|
BR112020001430A2
(pt)
|
2017-07-26 |
2020-07-28 |
Nissan Chemical Corporation |
oligonucleotídeo de fita simples
|
KR102687649B1
(ko)
|
2017-08-03 |
2024-07-26 |
신톡스, 인크. |
증식성 질환 및 감염성 질환의 치료를 위한 사이토카인 접합체
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
JP7313696B2
(ja)
*
|
2017-08-18 |
2023-07-25 |
ヨーロピアン モレキュラー バイオロジー ラボラトリー |
増強されたRNAインタラクトーム捕捉(eRIC)
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
GB2599884B
(en)
|
2017-08-25 |
2022-08-31 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
KR102380264B1
(ko)
|
2017-08-31 |
2022-03-29 |
주식회사 씨젠 |
다이머-형성 프라이머 쌍을 이용한 구성요소의 성능 평가
|
WO2019066461A2
(en)
|
2017-09-29 |
2019-04-04 |
Seegene, Inc. |
DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY CLEAVAGE ANALYSIS AND EXTENSION OF PTO
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
UA126931C2
(uk)
|
2017-10-16 |
2023-02-22 |
Ф. Хоффманн-Ля Рош Аг |
МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
|
WO2019076919A1
(en)
|
2017-10-17 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
COMBINED TREATMENT OF CYSTIC FIBROSIS
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
EP3704250A1
(en)
|
2017-11-03 |
2020-09-09 |
InteRNA Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
WO2019111791A1
(ja)
*
|
2017-12-07 |
2019-06-13 |
第一三共株式会社 |
ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
US11578323B2
(en)
|
2017-12-14 |
2023-02-14 |
Bayer Healthcare Llc |
RNA-programmable endonuclease systems and their use in genome editing and other applications
|
US11725208B2
(en)
|
2017-12-14 |
2023-08-15 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
US20200325532A1
(en)
|
2017-12-15 |
2020-10-15 |
Novartis Ag |
Polya tail length analysis of rna by mass spectrometry
|
US20200308588A1
(en)
|
2017-12-18 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
EP3729095A1
(en)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Companion diagnostic for htra1 rna antagonists
|
EP4092117A1
(en)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
JP7476102B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド
|
EP3728590A1
(en)
|
2017-12-22 |
2020-10-28 |
Roche Innovation Center Copenhagen A/S |
Novel thiophosphoramidites
|
EP3737758A1
(en)
|
2018-01-10 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
US20220119811A1
(en)
|
2018-01-12 |
2022-04-21 |
Roche Innovation Center Copenhagen A/S |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
PE20211749A1
(es)
|
2018-01-12 |
2021-09-06 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
|
JP7455746B2
(ja)
|
2018-01-12 |
2024-03-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
アルファ-シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用
|
EP3737760A1
(en)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
US20210095276A1
(en)
|
2018-01-17 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Srebp1を標的とするアンチセンスオリゴヌクレオチド
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
PE20211197A1
(es)
|
2018-02-09 |
2021-07-01 |
Genentech Inc |
Oligonucleotidos para modular la expresion de tmem106b
|
WO2019155094A1
(en)
|
2018-02-12 |
2019-08-15 |
Interna Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
AU2019218987A1
(en)
|
2018-02-12 |
2020-07-23 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
BR112020016347A2
(pt)
|
2018-02-21 |
2021-01-12 |
Bristol-Myers Squibb Company |
Oligonucleotídeos antisense de camk2d e seus usos
|
AR114445A1
(es)
|
2018-02-26 |
2020-09-09 |
Synthorx Inc |
Conjugados de il-15, y sus usos
|
US11958878B2
(en)
|
2018-03-09 |
2024-04-16 |
Daiichi Sankyo Company, Limited |
Therapeutic agent for glycogen storage disease type IA
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
|
AU2019237599A1
(en)
|
2018-03-20 |
2020-11-12 |
Nissan Chemical Corporation |
Antisense oligonucleotide having reduced toxicity
|
CA3097544A1
(en)
|
2018-04-05 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
EP3553182A1
(en)
|
2018-04-11 |
2019-10-16 |
Université de Bourgogne |
Detection method of somatic genetic anomalies, combination of capture probes and kit of detection
|
JP2021523227A
(ja)
|
2018-05-04 |
2021-09-02 |
ストーク セラピューティクス,インク. |
コレステリルエステル蓄積症の処置のための方法及び組成物
|
KR20210018267A
(ko)
|
2018-05-07 |
2021-02-17 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달
|
JP2021522808A
(ja)
|
2018-05-07 |
2021-09-02 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチド治療剤の超並列発見方法
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
MX2020011913A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de fxi.
|
FI3794122T3
(fi)
|
2018-05-14 |
2023-11-07 |
Alnylam Pharmaceuticals Inc |
Angiotensinogeenin (AGT) IRNA-koostumuksia ja niiden käyttömenetelmä
|
US20210220387A1
(en)
|
2018-05-18 |
2021-07-22 |
Hoffmann-La Roche, Inc. |
Pharmaceutical compositions for treatment of microrna related diseases
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
US11066669B2
(en)
|
2018-06-05 |
2021-07-20 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
CA3102236A1
(en)
|
2018-06-13 |
2019-12-19 |
Daiichi Sankyo Company, Limited |
Myocardial dysfunction therapeutic agent
|
JP2021528068A
(ja)
|
2018-06-21 |
2021-10-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
全lnaオリゴヌクレオチドのハイブリダイズ
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
MX2020013366A
(es)
|
2018-07-03 |
2021-03-09 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau.
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
WO2020022499A1
(ja)
|
2018-07-27 |
2020-01-30 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
WO2020025563A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
JP6544783B1
(ja)
|
2018-07-31 |
2019-07-17 |
学校法人 岩手医科大学 |
がんの診断のためのプローブ/プライマーライブラリー
|
JP2021532075A
(ja)
|
2018-07-31 |
2021-11-25 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロトリチオエートヌクレオシド間結合を含むオリゴヌクレオチド
|
WO2020028729A1
(en)
|
2018-08-01 |
2020-02-06 |
Mammoth Biosciences, Inc. |
Programmable nuclease compositions and methods of use thereof
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EA202190581A1
(ru)
|
2018-08-20 |
2021-07-13 |
Рогкон, Инк. |
Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
EP3844274A1
(en)
|
2018-08-28 |
2021-07-07 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
WO2020068398A2
(en)
|
2018-09-07 |
2020-04-02 |
The General Hospital Corporation |
Compositions and methods for immune checkpoint inhibition
|
EP3620520A1
(en)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Novel target to treat a metabolic disease in an individual
|
CN112912422A
(zh)
|
2018-09-14 |
2021-06-04 |
西北大学 |
用dna编程蛋白质聚合
|
WO2020060986A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
CA3114396A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020089260A1
(en)
|
2018-11-01 |
2020-05-07 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting tia1
|
US20220002336A1
(en)
|
2018-11-12 |
2022-01-06 |
Mitsubishi Tanabe Pharma Corporation |
Crosslinked artificial nucleic acid alna
|
EA202191342A1
(ru)
|
2018-11-15 |
2021-08-10 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии irf5
|
WO2020099533A1
(en)
|
2018-11-16 |
2020-05-22 |
F. Hoffmann-La Roche Ag |
Streptavidin-coated solid phases with a member of a binding pair
|
TWI841633B
(zh)
|
2018-11-21 |
2024-05-11 |
美商Ionis製藥公司 |
用於減少朊病毒表現之化合物及方法
|
EP3883941A1
(en)
|
2018-11-22 |
2021-09-29 |
Roche Innovation Center Copenhagen A/S |
Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
US20220042011A1
(en)
|
2018-12-21 |
2022-02-10 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotides targeting card9
|
WO2020142754A2
(en)
|
2019-01-04 |
2020-07-09 |
Mammoth Biosciences, Inc. |
Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
|
CA3126933A1
(en)
|
2019-01-16 |
2020-07-23 |
Genzyme Corporation |
Serpinc1 irna compositions and methods of use thereof
|
DE102019000490A1
(de)
|
2019-01-23 |
2020-07-23 |
HAEMES Verwaltungsgesellschaft mbH |
Verwendung von Oligonukleotiden für die Behandlung von Tumoren
|
CN113365607A
(zh)
|
2019-01-25 |
2021-09-07 |
豪夫迈·罗氏有限公司 |
用于口服药物递送的脂质囊泡
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
TW202102516A
(zh)
|
2019-02-20 |
2021-01-16 |
丹麥商羅氏創新中心哥本哈根有限公司 |
膦醯基乙酸酯間隙子寡核苷酸
|
CN113474352A
(zh)
|
2019-02-20 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
新型亚磷酰胺
|
WO2020173845A1
(en)
|
2019-02-26 |
2020-09-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
CN113507942A
(zh)
|
2019-03-05 |
2021-10-15 |
豪夫迈·罗氏有限公司 |
分子的细胞内靶向
|
WO2020181101A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
EP3937963A2
(en)
|
2019-03-12 |
2022-01-19 |
CRISPR Therapeutics AG |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
EP3981431A4
(en)
|
2019-03-14 |
2023-06-28 |
Rena Therapeutics Inc. |
Nucleic acid complex for modulating ihh expression
|
EP3941528A1
(en)
|
2019-03-21 |
2022-01-26 |
Codiak BioSciences, Inc. |
Extracellular vesicle conjugates and uses thereof
|
WO2020191177A1
(en)
|
2019-03-21 |
2020-09-24 |
Sudhir Agrawal |
Antisense oligonucleotides for allele specificity
|
JP7550165B2
(ja)
|
2019-03-29 |
2024-09-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Ube3a-atsを調節するための化合物及び方法
|
AU2020252710A1
(en)
|
2019-03-29 |
2021-11-11 |
Mitsubishi Tanabe Pharma Corporation |
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR DUX4 EXPRESSION ADJUSTMENT to COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
|
WO2020206115A2
(en)
|
2019-04-03 |
2020-10-08 |
Bristol-Myers Squibb Company |
Angptl2 antisense oligonucleotides and uses thereof
|
WO2020201339A1
(en)
|
2019-04-04 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
US20220194976A1
(en)
|
2019-04-16 |
2022-06-23 |
Roche Innovation Center Copenhagen A/S |
Novel Process for Preparing Nucleotide P(V) Monomers
|
WO2020221705A1
(en)
|
2019-04-30 |
2020-11-05 |
Roche Innovation Center Copenhagen A/S |
Novel process for preparing rhenium chelated mag3 oligonucleotides
|
EP3966328A4
(en)
|
2019-05-06 |
2023-10-18 |
University Of Massachusetts |
ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
|
AU2020279101A1
(en)
|
2019-05-17 |
2021-11-18 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
EP3976791A4
(en)
|
2019-05-28 |
2023-10-11 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING FOOT EXPRESSION
|
EP3976834A1
(en)
|
2019-05-31 |
2022-04-06 |
Streck, Inc. |
Detection of antibiotic resistance genes
|
BR112021024373A2
(pt)
|
2019-06-05 |
2022-01-18 |
Daiichi Sankyo Co Ltd |
Rna guia estável para edição de alvos tendo ácido nucleico quimicamente modificado introduzido a ele
|
CN113950529A
(zh)
|
2019-06-06 |
2022-01-18 |
豪夫迈·罗氏有限公司 |
靶向atxn3的反义寡核苷酸
|
CN113939599A
(zh)
|
2019-06-07 |
2022-01-14 |
豪夫迈·罗氏有限公司 |
杂交全lna寡核苷酸
|
CN114207129A
(zh)
|
2019-06-14 |
2022-03-18 |
斯克利普斯研究所 |
用于在半合成生物体中复制、转录和翻译的试剂和方法
|
EP3988558A4
(en)
|
2019-06-19 |
2022-09-28 |
Yamasa Corporation |
CROSSLINKED NUCLEOSIDE INTERMEDIATE CRYSTAL AND METHOD FOR PRODUCTION THEREOF, AND METHOD FOR PRODUCTION OF CROSSLINKED NUCLEOSIDE AMIDITE
|
CN114080238A
(zh)
|
2019-06-26 |
2022-02-22 |
神户天然物化学株式会社 |
抑制肌肉生长抑制素基因的mRNA的产生的核酸药物
|
CN110204583B
(zh)
*
|
2019-07-01 |
2021-03-23 |
中国人民解放军军事科学院军事医学研究院 |
修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
KR20220032004A
(ko)
|
2019-07-12 |
2022-03-15 |
다이이찌 산쿄 가부시키가이샤 |
DUX4 프리-mRNA의 스플라이싱을 변화시키는 안티센스 올리고뉴클레오티드
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
US20220267778A1
(en)
|
2019-07-30 |
2022-08-25 |
Shionogi & Co., Ltd. |
Nucleic acid drug targeting murf1
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
CA3147369A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting cebp/beta
|
JP2022544935A
(ja)
|
2019-08-14 |
2022-10-24 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
細胞外小胞-nlrp3アンタゴニスト
|
US20220354963A1
(en)
|
2019-08-14 |
2022-11-10 |
Codiak Biosciences, Inc. |
Extracellular vesicle linked to molecules and uses thereof
|
EP4013877A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
JP2022544934A
(ja)
|
2019-08-14 |
2022-10-24 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
Stat3-アンチセンスオリゴヌクレオチドを含む細胞外小胞
|
JP2022544290A
(ja)
|
2019-08-14 |
2022-10-17 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
Krasを標的とするアンチセンスオリゴヌクレオチドを有する細胞外小胞
|
CN114555621A
(zh)
|
2019-08-15 |
2022-05-27 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
US20220378920A1
(en)
|
2019-09-10 |
2022-12-01 |
Daiichi Sankyo Company, Limited |
CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
IT201900017234A1
(it)
|
2019-09-25 |
2021-03-25 |
Int Centre For Genetic Engineering And Biotechnology |
Anti-miRNA per il trattamento del leiomioma
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
CN110590886B
(zh)
*
|
2019-09-26 |
2021-03-23 |
中国人民解放军军事科学院军事医学研究院 |
修饰核苷、核苷酸和核酸聚合物及其制备方法与应用
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
KR20220083707A
(ko)
|
2019-10-18 |
2022-06-20 |
다이이찌 산쿄 가부시키가이샤 |
2 고리성 포스포르아미다이트의 제조 방법
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
JP2022553348A
(ja)
|
2019-10-22 |
2022-12-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分C3 iRNA組成物およびその使用方法
|
EP4052730A4
(en)
*
|
2019-10-28 |
2023-06-14 |
National University Corporation Tokai National Higher Education and Research System |
NUCLEOSIDE DERIVATIVE AND USE THEREOF
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
CN114945669A
(zh)
|
2019-11-06 |
2022-08-26 |
阿尔尼拉姆医药品有限公司 |
肝外递送
|
BR112022009216A2
(pt)
|
2019-11-13 |
2022-08-02 |
Alnylam Pharmaceuticals Inc |
Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
CN115335521A
(zh)
|
2019-11-27 |
2022-11-11 |
克里斯珀医疗股份公司 |
合成rna分子的方法
|
CN115176001A
(zh)
|
2019-12-11 |
2022-10-11 |
因特利亚治疗公司 |
用于基因编辑的修饰的引导rna
|
TW202140509A
(zh)
|
2019-12-13 |
2021-11-01 |
美商阿尼拉製藥公司 |
人類染色體9開讀框72(C9ORF72)iRNA劑組成物及其使用方法
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
JP7500727B2
(ja)
|
2019-12-18 |
2024-06-17 |
エフ. ホフマン-ラ ロシュ アーゲー |
連続的な標識スキームを使用した合成による配列決定方法
|
CN114829599A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
|
CN114901821A
(zh)
|
2019-12-19 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
|
WO2021122993A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of saraf inhibitors for treating hepatitis b virus infection
|
JP2023506550A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用
|
WO2021122921A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
US20210214727A1
(en)
|
2019-12-20 |
2021-07-15 |
Hoffmann-La Roche Inc. |
Enhanced oligonucleotides for inhibiting scn9a expression
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
TW202137987A
(zh)
|
2019-12-24 |
2021-10-16 |
瑞士商赫孚孟拉羅股份公司 |
用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
|
JPWO2021153747A1
(xx)
|
2020-01-31 |
2021-08-05 |
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
MX2022009763A
(es)
|
2020-02-10 |
2022-09-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
|
TWI794742B
(zh)
|
2020-02-18 |
2023-03-01 |
美商基利科學股份有限公司 |
抗病毒化合物
|
WO2021167841A1
(en)
|
2020-02-18 |
2021-08-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
US12030903B2
(en)
|
2020-02-18 |
2024-07-09 |
Gilead Sciences, Inc. |
Antiviral compounds
|
TWI775313B
(zh)
|
2020-02-18 |
2022-08-21 |
美商基利科學股份有限公司 |
抗病毒化合物
|
AU2021225957A1
(en)
|
2020-02-28 |
2022-09-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating SMN2
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
EP4116419A1
(en)
|
2020-03-04 |
2023-01-11 |
Nissan Chemical Corporation |
Antisense oligonucleotide of calm2
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
BR112022017822A2
(pt)
|
2020-03-06 |
2022-11-08 |
Alnylam Pharmaceuticals Inc |
Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
|
CN115461460A
(zh)
|
2020-03-06 |
2022-12-09 |
阿尔尼拉姆医药品有限公司 |
用于抑制转甲状腺素蛋白(ttr)的表达的组合物和方法
|
JP6953053B1
(ja)
|
2020-03-11 |
2021-10-27 |
隆光 矢野 |
−1フレームシフトを誘導するための1本鎖核酸分子及び組成物
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
コロナウイルスiRNA組成物およびその使用方法
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
WO2021198883A1
(en)
|
2020-03-31 |
2021-10-07 |
Janssen Biopharma, Inc. |
Synthesis of oligonucleotides and related compounds
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
IL297130A
(en)
|
2020-04-07 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing scn9a expression
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
IL297680A
(en)
|
2020-04-30 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
IRNA compounds complement factor b (cfb) and methods of using them
|
WO2021231211A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
KR20230022409A
(ko)
|
2020-05-11 |
2023-02-15 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
CN115605592A
(zh)
|
2020-05-11 |
2023-01-13 |
基因泰克公司(Us) |
用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
|
US20230227824A1
(en)
|
2020-05-12 |
2023-07-20 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for regulating expression of ataxin 3
|
US20210388357A1
(en)
|
2020-05-13 |
2021-12-16 |
Hoffmann-La Roche Inc. |
Oligonucleotide agonists targeting progranulin
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
JP2023526096A
(ja)
|
2020-05-22 |
2023-06-20 |
エフ. ホフマン-ラ ロシュ アーゲー |
Card9のスプライス調節のためのオリゴヌクレオチド
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
EP4168546A1
(en)
|
2020-06-18 |
2023-04-26 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
CN111732623B
(zh)
*
|
2020-06-30 |
2022-01-18 |
中国科学院化学研究所 |
一种三异丙基硅乙炔修饰的脱氧胞苷亚磷酰胺单体及其制备方法与应用
|
US20220002716A1
(en)
|
2020-07-02 |
2022-01-06 |
Life Technologies Corporation |
Trinucleotide cap analogs, preparation and uses thereof
|
WO2022008935A1
(en)
|
2020-07-10 |
2022-01-13 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
AU2021305665A1
(en)
|
2020-07-10 |
2023-02-23 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating epilepsy
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
JP2023534557A
(ja)
|
2020-07-23 |
2023-08-09 |
エフ. ホフマン-ラ ロシュ アーゲー |
Rna結合タンパク質部位を標的とするオリゴヌクレオチド
|
CN115916976A
(zh)
|
2020-07-28 |
2023-04-04 |
神户天然物化学株式会社 |
诱导血管紧张素转换酶2基因外显子跳跃的反义核酸
|
EP4200419A2
(en)
|
2020-08-21 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
JPWO2022097727A1
(xx)
|
2020-11-06 |
2022-05-12 |
|
|
WO2022103999A1
(en)
|
2020-11-13 |
2022-05-19 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US20230416734A1
(en)
|
2020-11-18 |
2023-12-28 |
Lemba Bv |
Umlilo antisense transcription inhibitors
|
CA3201661A1
(en)
|
2020-11-18 |
2022-05-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
US20240002853A1
(en)
|
2020-11-23 |
2024-01-04 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
AR124227A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
JP2023553069A
(ja)
|
2020-12-08 |
2023-12-20 |
エフ. ホフマン-ラ ロシュ アーゲー |
ホスホロジチオエートオリゴヌクレオチドの新規合成
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
TW202237837A
(zh)
|
2020-12-08 |
2022-10-01 |
學校法人福岡大學 |
經導入化學修飾核酸之穩定型標的編輯引導rna
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
CN116472276A
(zh)
*
|
2020-12-11 |
2023-07-21 |
雅玛山酱油株式会社 |
胞嘧啶型交联型核苷亚磷酰胺晶体及其制造方法
|
CN116583603A
(zh)
|
2020-12-18 |
2023-08-11 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的反义寡核苷酸
|
WO2022133278A2
(en)
|
2020-12-18 |
2022-06-23 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor xii
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ. ホフマン-ラ ロシュ アーゲー |
Xbp1を標的とするオリゴヌクレオチド
|
JP2024501857A
(ja)
|
2020-12-31 |
2024-01-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
|
EP4271695A2
(en)
|
2020-12-31 |
2023-11-08 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
KR20230146048A
(ko)
|
2021-02-12 |
2023-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
|
KR20230144588A
(ko)
|
2021-02-12 |
2023-10-16 |
머랜드 파마슈티칼스, 인크. |
저산소증 및 허혈-관련 장애의 치료를 위한 작용제, 조성물 및 방법
|
CA3207944A1
(en)
|
2021-02-17 |
2022-08-25 |
Ajay Verma |
Extracellular vesicle-nlrp3 antagonist
|
EP4294456A1
(en)
|
2021-02-17 |
2023-12-27 |
Lonza Sales AG |
Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
|
WO2022182864A1
(en)
|
2021-02-25 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods and methods of use thereof
|
US20240229036A9
(en)
|
2021-02-26 |
2024-07-11 |
Knc Laboratories Co., Ltd. |
Nucleic acid medicine expressing splicing variant of myostatin
|
EP4298218A1
(en)
|
2021-02-26 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2022187435A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
KR20230170690A
(ko)
|
2021-03-26 |
2023-12-19 |
뉴미르나 테라퓨틱스 에이피에스 |
MicroRNA-134 억제제들
|
EP4313074A1
(en)
|
2021-03-26 |
2024-02-07 |
Neumirna Therapeutics ApS |
Microrna-27b inhibitors
|
MX2023011466A
(es)
|
2021-03-29 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas.
|
WO2022213118A1
(en)
|
2021-03-31 |
2022-10-06 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
JP2024513841A
(ja)
|
2021-04-01 |
2024-03-27 |
ロンザ セールス アーゲー |
細胞外小胞組成物
|
CA3216162A1
(en)
|
2021-04-16 |
2022-10-20 |
Gilead Sciences, Inc. |
Methods of preparing carbanucleosides using amides
|
EP4330392A1
(en)
|
2021-04-26 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4337263A1
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
EP4337264A1
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating tissue distribution of intracellular therapeutics
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
KR20240016342A
(ko)
|
2021-05-31 |
2024-02-06 |
레나 테라퓨틱스 인크. |
리간드-결합 핵산 복합체
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
KR20240017911A
(ko)
|
2021-06-04 |
2024-02-08 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 해독 프레임 72(C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
CN117677710A
(zh)
|
2021-06-04 |
2024-03-08 |
翻译生物公司 |
用于定量评估mRNA加帽效率的测定
|
WO2022254021A1
(en)
|
2021-06-04 |
2022-12-08 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
EP4352222A1
(en)
|
2021-06-08 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Oligonucleotide progranulin agonists
|
WO2022261292A1
(en)
|
2021-06-10 |
2022-12-15 |
Intellia Therapeutics, Inc. |
Modified guide rnas comprising an internal linker for gene editing
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
BR112023023768A2
(pt)
|
2021-06-11 |
2024-02-27 |
Bayer Ag |
Sistemas de endonucleases programáveis por rna tipo v
|
BR112023027308A2
(pt)
|
2021-06-22 |
2024-03-12 |
AcuraStem Incorporated |
Oligonucleotídeos antisense pikfyve
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
EP4372329A1
(en)
|
2021-07-12 |
2024-05-22 |
Seegene, Inc. |
Method and system for determining height of solution accommodated in container
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
IL310303A
(en)
|
2021-07-21 |
2024-03-01 |
Acurastem Inc |
UNC13A mol-read oligonucleotides
|
AU2022314619A1
(en)
|
2021-07-21 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
TW202325312A
(zh)
|
2021-07-23 |
2023-07-01 |
美商艾拉倫製藥股份有限公司 |
β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法
|
EP4377458A1
(en)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
JP2024531914A
(ja)
|
2021-08-04 |
2024-09-03 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンジオテンシノーゲン(agt)をサイレンシングするためのirna組成物および方法
|
AU2022328347A1
(en)
|
2021-08-13 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
EP4389892A1
(en)
|
2021-08-17 |
2024-06-26 |
Korea Advanced Institute of Science and Technology |
Antisense oligonucleotide targeting cav3.1 gene and uses thereof
|
AU2022329462A1
(en)
|
2021-08-19 |
2024-03-28 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
MX2024002640A
(es)
|
2021-09-01 |
2024-07-19 |
Entrada Therapeutics Inc |
Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
EP4401742A2
(en)
|
2021-09-17 |
2024-07-24 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
EP4403645A1
(en)
|
2021-09-17 |
2024-07-24 |
Seegene, Inc. |
Detection of target nucleic acid sequence by using synthetic non-natural base-bearing tag oligonucleotide
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023052317A1
(en)
|
2021-09-29 |
2023-04-06 |
F. Hoffmann-La Roche Ag |
Rna editing
|
MX2024004011A
(es)
|
2021-10-01 |
2024-07-01 |
Adarx Pharmaceuticals Inc |
Composiciones moduladoras de precalicreína y métodos de uso de estas.
|
AU2022364838A1
(en)
|
2021-10-15 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
AU2022370009A1
(en)
|
2021-10-22 |
2024-05-16 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
EP4423272A2
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
EP4423273A1
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
EP4428238A1
(en)
|
2021-11-02 |
2024-09-11 |
Rena Therapeutics Inc. |
Ligand-bound nucleic acid complex
|
EP4426833A1
(en)
|
2021-11-03 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating apolipoprotein e4 expression
|
IL312635A
(en)
|
2021-11-11 |
2024-07-01 |
Hoffmann La Roche |
Pharmaceutical combinations for the treatment of HBV
|
AU2022391744A1
(en)
|
2021-11-18 |
2024-06-27 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
US20230159930A1
(en)
|
2021-11-19 |
2023-05-25 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
|
CN118434858A
(zh)
|
2021-12-07 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
靶向actl6b的反义寡核苷酸
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
CN118489009A
(zh)
|
2021-12-17 |
2024-08-13 |
豪夫迈·罗氏有限公司 |
寡核苷酸gba激动剂
|
CN118434860A
(zh)
|
2021-12-20 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
苏糖核酸反义寡核苷酸及其方法
|
IL313660A
(en)
|
2021-12-22 |
2024-08-01 |
Camp4 Therapeutics Corp |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
CN118613268A
(zh)
|
2022-01-20 |
2024-09-06 |
基因泰克公司 |
用于调节tmem106b表达的反义寡核苷酸
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
US20240167040A1
(en)
|
2022-02-21 |
2024-05-23 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotide
|
WO2023212625A1
(en)
|
2022-04-28 |
2023-11-02 |
AcuraStem Incorporated |
Syf2 antisense oligonucleotides
|
WO2023220561A1
(en)
|
2022-05-09 |
2023-11-16 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
AR129362A1
(es)
|
2022-05-18 |
2024-08-14 |
Hoffmann La Roche |
Oligonucleótidos mejorados que actúan sobre sitios de proteína de unión de arn
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
US20240052348A1
(en)
|
2022-08-05 |
2024-02-15 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
EP4332239A1
(en)
|
2022-08-30 |
2024-03-06 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
|
TW202421206A
(zh)
|
2022-09-06 |
2024-06-01 |
瑞士商赫孚孟拉羅股份公司 |
用於投予至眼睛之雙股rna分子
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024073042A1
(en)
|
2022-09-30 |
2024-04-04 |
Entrada Therapeutics, Inc. |
Ocular delivery of therapeutic agents
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
WO2024081954A2
(en)
|
2022-10-14 |
2024-04-18 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
WO2024104914A1
(en)
|
2022-11-14 |
2024-05-23 |
BioNTech SE |
Rna capping efficiency assay
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
WO2024137590A2
(en)
|
2022-12-19 |
2024-06-27 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting cfb and uses thereof
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
WO2024155986A2
(en)
|
2023-01-20 |
2024-07-25 |
AcuraStem Incorporated |
Unc13a antisense oligonucleotides
|
WO2024160756A1
(en)
|
2023-01-30 |
2024-08-08 |
Vib Vzw |
Suppressors of tauopathies
|
WO2024163651A2
(en)
|
2023-01-31 |
2024-08-08 |
AcuraStem Incorporated |
Syf2 antisense oligonucleotides
|
WO2024167945A1
(en)
|
2023-02-06 |
2024-08-15 |
AcuraStem Incorporated |
Pikfyve antisense oligonucleotides
|
WO2024168010A2
(en)
|
2023-02-09 |
2024-08-15 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2024175707A1
(en)
|
2023-02-22 |
2024-08-29 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
A synthetic oligonucleotide for treating nidovirales infections
|
US20240309383A1
(en)
|
2023-02-24 |
2024-09-19 |
Suzhou Sanegene Bio Inc. |
Small interfering rna targeting hbv and uses thereof
|
US20240309380A1
(en)
|
2023-03-03 |
2024-09-19 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting apoc3 and uses thereof
|